

## Quantification of Lipid Corona Formation on Colloidal Nanoparticles from Lipid Vesicles

Xi Zhang, Arun Kumar Pandiakumar, Robert J Hamers, and Catherine J. Murphy

*Anal. Chem.*, Just Accepted Manuscript • DOI: 10.1021/acs.analchem.8b03911 • Publication Date (Web): 14 Nov 2018

Downloaded from <http://pubs.acs.org> on November 20, 2018

### Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



ACS Publications

is published by the American Chemical Society, 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

### Quantification of Lipid Corona Formation on Colloidal Nanoparticles from Lipid Vesicles

Xi Zhang<sup>†</sup>, Arun Kumar Pandiakumar<sup>‡</sup>, Robert J. Hamers<sup>‡</sup> and Catherine J. Murphy<sup>\*†</sup>

<sup>†</sup> Department of Chemistry, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana, Illinois 61801, United States

<sup>‡</sup> Department of Chemistry, University of Wisconsin—Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States

\*to whom correspondence should be addressed: murphycj@illinois.edu

#### ABSTRACT

Formation of a protein corona around nanoparticles when immersed into biological fluids is well-known; less studied is the formation of lipid coronas around nanoparticles. In many cases, the identity of a nanoparticle-acquired corona determines nanoparticle fate within a biological system and its interactions with cells and organisms. This work systematically explores the impact of nanoparticle surface chemistry and lipid character on the formation of lipid coronas for three different nanoparticle surface chemistries (two cationic, one anionic) on 14 nm gold nanoparticles exposed to a series of lipid vesicles of four different compositions. Qualitative (plasmon band shifting,  $\zeta$  potential analysis, dynamic light scattering on the part of the nanoparticles) and quantitative (lipid liquid chromatography/mass spectrometry) methods are developed with a “pull-down” scheme to assess the degree of lipid corona formation in these systems. In general, cationic nanoparticles extract 60–95% of the lipids available in vesicles under the described experimental conditions, while anionic nanoparticles extract almost none. While electrostatics apparently dominate the lipid-nanoparticle interactions, primary amine polymer surfaces extract more lipids

1  
2  
3 than quaternary ammonium surfaces. Free cationic species can act as lipid-binding competitors in  
4  
5 solution.  
6  
7  
8  
9  
10

## 11 INTRODUCTION 12

13  
14 Nanotechnology is one of the enabling technologies of the twenty-first century. Much progress has  
15 been made in controlling material composition and structure at the nanoscale, which leads to  
16 control of the physicochemical properties and function of nanomaterials.<sup>1</sup> In particular, gold  
17 nanoparticles (AuNPs) are of particular interest due to their relative chemical inertness, versatile  
18 surface chemistry, and unique optical properties, allowing applications in diagnostics, imaging,  
19 drug delivery, and therapeutics.<sup>2–7</sup> In the context of these biological applications, knowledge of  
20 the interaction of nanomaterials with biomolecules, cells, and organisms is critical,<sup>8,9</sup> and concerns  
21 about potential environmental, health, and safety issues have been raised.<sup>10–12</sup> How do  
22 nanomaterials interact with their surroundings, and what are the molecular mechanisms driving  
23 those interactions? Answers to these questions will improve the design of nanomaterials to retain  
24 function while minimizing detrimental effects.<sup>13,14</sup>  
25  
26

27 When nanoparticles are exposed to biological or natural environments, they are known to acquire  
28 a coating (“corona”) of biomolecules.<sup>15–17</sup> While much work to date has focused on protein coronas,  
29 fewer studies examine other biomolecular coronas such as lipid coronas.<sup>18,19</sup> In one recent example,  
30 lipids, along with proteins, were found to attach to nanoparticles when interacting with pulmonary  
31 surfactant.<sup>19</sup> Also, computational simulations suggest that lipid coronas form on nanoparticles with  
32 specific surface chemistries.<sup>20–22</sup>  
33  
34

35 Since cellular membranes are composed primarily of phospholipid bilayers, forming the frontier  
36  
37  
38

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 between the cell and its environment,<sup>23</sup> the membrane can be considered as one of the initial points  
4 of contact between a nanomaterial and a living system. Supported lipid bilayers and suspended  
5 lipid vesicles are commonly used as models for phospholipid cell membranes; suspended lipid  
6 vesicles are good models for intracellular organelles.<sup>24-28</sup> Recent collaborative work from our  
7 laboratory showed lipid corona formation on polycation-wrapped gold nanoparticles upon  
8 interaction with anionic supported lipid bilayers via several techniques including  $\zeta$ -potential  
9 measurement, single molecule imaging, and molecular dynamics simulations.<sup>29</sup> Analysis of  
10 colloidal nanoparticles via centrifugation-based assays have been used to determine corona-  
11 nanoparticle interactions.<sup>30,31</sup>

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25 Developing quantitative relationships between observables can help predict the biological  
26 responses to nanoparticles and eventually assist in uncovering the fundamental mechanisms of  
27 nano-bio interactions.<sup>32</sup> Therefore, the goal of this study is to quantify the degree of lipid binding  
28 to nanoparticles in colloidal solution: the lipids are in the form of vesicles, to simulate organelles.  
29  
30 A centrifugation-based pull-down assay was developed wherein three AuNPs were incubated with  
31 suspended phospholipid vesicles of varied composition; lipids associated with the AuNPs were  
32 pulled down via centrifugation, and remaining lipids were left in the supernatant. UV-visible  
33 spectroscopy, dynamic light scattering (DLS), and laser Doppler electrophoresis measurements  
34 were performed on the AuNPs, while quantitative liquid chromatography-tandem mass  
35 spectrometry (LC-MS/MS) experiments quantified lipids in each fraction.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 **MATERIALS AND METHODS**

50  
51  
52 *Materials.* Gold(III) chloride trihydrate ( $\text{HAuCl}_4 \cdot 3\text{H}_2\text{O}$ ,  $\geq 99.9\%$ ), sodium citrate tribasic dihydrate  
53 ( $\text{Na}_3\text{Ct} \cdot 2\text{H}_2\text{O}$ ,  $\geq 99\%$ ), poly(allylamine) hydrochloride (PAH) ( $\sim 17500 \text{ g mol}^{-1}$ ), sodium chloride  
54  
55  
56  
57  
58  
59  
60

(NaCl), and (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) were obtained from Sigma-Aldrich and used as received. 16-(Mercaptohexadecyl)trimethylammonium bromide (MTAB) was prepared according Zubarev *et al.* (see Supporting Information for detailed procedures and characterization).<sup>33</sup> The lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), 1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol (DOPG), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids. All solutions were prepared in 18 MΩ·cm nanopure water. Glassware was cleaned prior to synthesis using aqua regia (*Caution!*) and then rinsed with nanopure water.

*Citrate-AuNPs synthesis.* We synthesized AuNPs of 14 nm diameter, capped with citrate, by the Turkevich method.<sup>34</sup> Briefly, 1.25 mL of 0.1 M HAuCl<sub>4</sub>·3H<sub>2</sub>O was added to 498.75 mL of ultrapure water, and the solution was heated to a rolling boil. Then, 10 mL of 1% w/w sodium citrate was added, and the solution was kept boiling for an additional 40 min. After the heat was turned off, the solution was allowed to cool naturally, and an additional 2.5 mL of 1% w/w sodium citrate was added. To purify, the AuNPs were centrifuged at 8000g for 20 min twice unless stated otherwise. The supernatant was discarded, and the remaining sample was redispersed in nanopure water. To calculate concentrations of the AuNPs, an extinction coefficient of  $2.18 \times 10^8 \text{ M}^{-1} \text{ cm}^{-1}$  was used.<sup>35</sup>

*Wrapping Citrate-AuNPs with PAH.* A 20 mL solution of 2 nM Citrate-AuNPs was prepared in a 50 mL centrifuge tube. In another tube, 2 mL of 0.01 M NaCl was mixed with 4 mL of 10 mg mL<sup>-1</sup> PAH. The PAH solution was then added to the AuNP solution. The tube was placed on a BellyDancer shaker overnight to mix, and the nanoparticle solution was purified by centrifugation at 8000g for 20 min twice unless stated otherwise. The final pellet of PAH-AuNPs was resuspended in 10 mM HEPES buffer (1 mM NaCl, pH 7.4).

1  
2  
3 *Coating Citrate-AuNPs with MTAB.* A 1.0 mL aqueous solution of 1.5 mg mL<sup>-1</sup> MTAB was heated  
4 at 60 °C for 30 min to achieve dissolution. Subsequently, 0.30 mL of 300 nM 15 nm AuNPs were  
5 added to the MTAB solution. The solution was kept at 60 °C overnight and purified by  
6 centrifugation at 8000g for 20 min twice unless stated otherwise. The final pellet of MTAB-AuNPs  
7 was resuspended in 10 mM HEPES buffer (1 mM NaCl, pH 7.4).  
8  
9  
10  
11  
12  
13  
14  
15

16 *Lipid vesicle preparation.* Small unilamellar vesicles were prepared by a sonication method  
17 previously described by the Morrissey Lab at UIUC (<https://tf7.org/suv.pdf>). Briefly, lipid  
18 mixtures in chloroform were combined to the desired ratio (pure DOPC, 9:1 DOPC/DOPS, 9:1  
19 DOPC/DOPG, 9:1 DOPC/DOPE), and vortexed for 30 s in a glass vial to achieve a homogenous  
20 mixture. The solvent was evaporated under a stream of ultrapure N<sub>2</sub> gas, and the dried film was  
21 placed in vacuum for additional 2 h. The dried lipid film was rehydrated to a 1 mg mL<sup>-1</sup> stock  
22 solution in 10 mM HEPES buffer (1 mM NaCl, pH 7.4) for 1 h. The rehydrated lipid solution was  
23 vortexed for 1 min to a milky solution, then was placed in a bath sonicator until the suspension  
24 changes from milky to nearly clear in appearance (~15 min for DOPC/DOPG and DOPC/DOPS,  
25 ~30 min for DOPC and DOPC/DOPE). Final lipid vesicle solutions were stored at 4 °C and used  
26 within 2 days. The lipid vesicles were characterized by DLS and laser Doppler electrophoresis.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

43 *Nanoparticle and lipid vesicles interactions.* All experiments and analyses were conducted in 10  
44 mM HEPES buffer (1 mM NaCl, pH 7.4). In a typical experiment, unless stated otherwise, 500 μL  
45 2.4 nM AuNPs were added to 500 μL 1 μg mL<sup>-1</sup> diluted as-prepared lipid vesicles in glass vials.  
46 Controls were done with an equivalent of same buffer in place of the colloidal gold solution, which  
47 take into account any potential losses of lipids due to adsorption to vials, etc. during processing.  
48 The combined solutions were mixed gently well before storage at room temperature overnight  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

(~18h) to achieve equilibrium. All samples were prepared in triplicate. After incubation, the solutions were transferred to 1.5 mL Eppendorf tubes and centrifuged at 16,000g for 50 min to achieve a clear separation. The AuNPs were redispersed in buffer and characterized by several methods, while the supernatants, containing free lipids, were quantified via LC-MS/MS. The concentration of lipids bound to AuNPs was equated, by mass balance, to the concentration in the control ( $C_{total}$ ) minus the concentration in the supernatant ( $C_{supernatant}$ ) to get the concentration of nanoparticle-bound lipids ( $C_{bound}$ ), and bound lipid percentage of total ( $C_{bound}/C_{total}$ ).


*Nanoparticle and lipid vesicle characterization and instrumentation.* Absorption spectra of all AuNPs were taken on a Cary 500 scan UV-vis-near-IR spectrophotometer. Transmission electron microscopy (TEM) data of AuNPs were obtained with a JEOL 2100 cryo electron microscope operating at 200 kV. DLS and laser Doppler electrophoresis were conducted on a Brookhaven ZetaPALS instrument. For lipid quantification, samples were analyzed with a 5500 QTRAP LC/MS/MS system (Sciex, Framingham, MA) in the Metabolomics Lab of the Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign. Details are described in the Supporting Information.

## RESULTS AND DISCUSSION

For this study, 14 nm diameter AuNPs with either an anionic ligand: sodium citrate (Citrate-AuNPs) or two different cationic ligands: 16-mercaptophexadecyltrimethylammonium bromide (MTAB-AuNPs) or poly(allylamine) hydrochloride (PAH-AuNPs) were studied. MTAB displays a quaternary ammonium group to the solvent while PAH displays primary amines (Figure 1). We chose PAH as a coating because it is a common polyelectrolyte wrapping for nanoparticles, widely

used in studies concerning nanoparticle organismal toxicity, lipid membrane interactions, and more.<sup>36-38</sup> In previous studies in our group, we found PAH-AuNPs promoted protein aggregation and beta-sheet formation whereas MTAB-AuNPs did not, even when the AuNPs possessed similar  $\zeta$ -potentials, suggesting that protein behavior on NPs cannot be predicted by surface potential alone.<sup>39,40</sup> The question, then, is to what extent do lipids also distinguish molecular-level details of nanoparticle surfaces. The suspended lipid vesicles were made in four combinations: pure zwitterionic DOPC, and DOPC containing 10% anionic DOPS, anionic DOPG, or zwitterionic DOPE. These DOPC-rich lipid vesicles were chosen because the zwitterionic PC headgroup is one of the most abundant headgroups in biological membranes.<sup>41,42</sup>

The workflow for the lipid corona-nanoparticle experiments is shown in Figure 1e.



**Figure 1.** Schematic of a) Citrate-AuNPs, b) MTAB-AuNPs, c) PAH-AuNPs, d) structures of lipids, e) Experimental workflow for quantification of lipid coronas on gold nanoparticles. After incubation with lipid vesicles, gold nanoparticles are centrifuged to separate free from bound lipid. Lipid quantification is performed by LC-MS/MS in the supernatants compared to standards in the same buffer system as the original incubation; total lipid – free lipids = bound lipids. Figures are


1  
2  
3 not drawn to scale, and the state of the lipids upon and after incubation with nanoparticles (vesicle  
4  
5 vs. free) is not known.  
6  
7  
8  
9

10 *AuNPs and lipid vesicle characterizations.* All AuNPs before lipid incubation were well  
11 characterized. The UV-vis spectra of representative batches of Citrate-AuNPs, MTAB-AuNPs and  
12 PAH-AuNPs are shown in Figure S1. The plasmon band maximum at ~520 nm is consistent with  
13 AuNPs of this size, and slight shifts in the plasmon peak are expected due to the change in local  
14 refractive index at the surface for the different surface groups.<sup>43</sup> The plasmon bands broaden  
15 slightly after functionalization, indicating a small amount of aggregation. The increase in  
16 hydrodynamic diameters( $d_h$ ) derived from DLS measurements and the  $\zeta$ -potentials calculated from  
17 electrophoretic mobilities for AuNPs in buffer further show the success of AuNPs  
18 functionalization (Table S1). TEM images (Figure S2) and the associated histograms (Figure S3)  
19 indicate that representative Citrate-AuNPs possessed a core diameter of  $14.2 \pm 1.6$  nm, MTAB-  
20 AuNPs  $13.9 \pm 1.5$  nm, PAH-AuNPs  $14.5 \pm 1.7$  nm ( $n > 200$ ).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The data in Table S2 indicate that the hydrodynamic diameters of lipid vesicles range from  
37 approximately 70 to 150 nm in diameter on average. We used 100 nm as an average size to estimate  
38 the molar concentration of  $1 \mu\text{g mL}^{-1}$  lipid vesicles (see SI for calculation), which is  $M_{\text{lipid}} =$   
39  $1.27 \times 10^{-6} \text{ M}$ . As designed for these experiments, with the addition of 2.4 nM AuNPs, the number  
40 ratio of AuNP:lipid vesicle is approximately 150:1, which is also within a range reported  
41 previously.<sup>44</sup> Based on their average composition, the  $\zeta$ -potential of DOPC vesicles and 9:1  
42 DOPC/DOPE vesicles are close to neutral because they are zwitterionic lipids, whereas 9:1  
43 DOPC/DOPS and 9:1 DOPC/DOPG are negatively charged as DOPS and DOPG are both anionic  
44 lipids. It is worth mentioning that while extrusion is also a common method for lipid vesicle  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 production, in our hands it led to more variability in final lipid vesicle concentration than  
4 sonication; therefore, we chose sonication over extrusion for making vesicles.  
5  
6


7  
8 *Anionic Citrate-AuNPs interactions with 4 types of lipid vesicles.* To validate the hypothesis that  
9 electrostatic attraction is one of the main forces driving nanoparticle-lipid vesicle interactions, we  
10 incubated anionic Citrate-AuNPs with the anionic lipid vesicles. As shown in Figure 2a, the  
11 extinction spectra of Citrate-AuNPs did not exhibit shifts in the plasmon maximum following  
12 interaction with any vesicle systems, after redispersion of the pellets after separation from free  
13 lipids. A slight broadening at longer wavelengths was observed, possibly due to the aggregation  
14 caused by high centrifugation force. No significant changes in hydrodynamic diameters or  $\zeta$ -  
15 potential were observed, and analysis of the LC-MS/MS data by comparing  $C_{bound}/C_{total}$  indicated  
16 minimal lipid was bound to the Citrate-AuNPs (Figure 2b-d). This data also demonstrates that ~5%  
17 or less of the lipids end up in the pellet, if NP-lipid electrostatics are not in favor of lipid-NP  
18 binding. Control experiments of lipid vesicles without undergoing the centrifugation process (data  
19 not shown) were also compared to the controls being centrifuged, showing that these centrifugation  
20 conditions did not sediment lipids ( $p > 0.05$ ,  $n > 30$ ). These data suggested no/little lipid coronas  
21 were formed on Citrate-AuNPs, presumably due to the electrostatic repulsion between anionic  
22 phospholipids and anionic nanoparticles. (No measurements were made to quantify any citrate  
23 desorption, but if lipids simply replaced citrate on the nanoparticles, we would have expected to  
24 bind nearly all of the lipids, based on the available surface area of the nanoparticles).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 2.** a) UV-vis spectra of Citrate-AuNPs before interaction(red), after interaction with DOPC(blue), 9:1 DOPC/DOPS(green), 9:1 DOPC/DOPG(orange), 9:1 DOPC/DOPE(black); b) DLS and c)  $\zeta$ -potential of Citrate-AuNPs before interaction (red), after interaction with DOPC (blue), 9:1 DOPC/DOPS (yellow), 9:1 DOPC/DOPG(green), 9:1 DOPC/DOPE(purple); d) LC-MS/MS quantification:  $C_{\text{bound}}/C_{\text{total}}$  (blue: DOPC, red: DOPS, orange: DOPG, green: DOPE). Bar heights represent mean values; error bars correspond to one standard deviation for triplicate runs from the same batches of nanoparticle and lipid vesicle solutions.

*Cationic MTAB-AuNPs and PAH-AuNPs interactions with 4 types of lipid vesicles.* Incubation experiments of cationic AuNPs were performed to assess the ability of AuNPs to acquire lipid coronas from vesicles. The hydrodynamic diameters and  $\zeta$ -potentials of AuNPs and vesicles are reported in Table S2("Figure 5 data"). Upon addition of PAH-AuNPs to vesicle solutions, the samples gradually aggregated, leading to sedimentation. In contrast, no visual aggregation was observed for MTAB-AuNPs, despite the similar  $\zeta$ -potentials of two AuNPs. UV-vis spectra (Figure 3) of the MTAB-AuNPs before and after vesicle incubation and subsequent separation, showed a slight red shift of ~5 nm in the plasmon maximum, suggesting lipid attachment.<sup>45</sup> For PAH-AuNPs, the original peak at ~520 nm was damped, and a new, broadened peak at a longer

wavelength (ranging from 619 to 653 nm) appeared after, indicative of aggregation.<sup>46</sup> These spectroscopic data support the notion that lipid corona formation occurs on MTAB-AuNPs, but for PAH-AuNPs, spectroscopic evidence for lipid corona formation is convoluted with lipid-induced aggregation.




**Figure 3.** Representative normalized extinction spectra of ~7 nM MTAB-AuNP (red) and PAH-AuNPs (blue) before (solid) and after (dashed) lipid pull-down experiment with a) DOPC, b) 9:1 DOPC/DOPS, c) 9:1 DOPC/DOPG, d) 9:1 DOPC/DOPE.

The hydrodynamic diameters of AuNPs before interaction and lipid-AuNP conjugates after pull-down were measured by DLS. As shown in Figure 4a-d, the hydrodynamic diameters of the MTAB-AuNPs increase by 5-10 nm after addition of vesicles, indicative of the formation of a nanoscale lipid layer(s). A dramatic increase in hydrodynamic diameters of PAH-AuNPs after vesicle incubation, for all lipid systems, indicates aggregation, consistent with both visual observations and UV-vis spectra.

After incubation with DOPC or 9:1 DOPC/DOPE vesicles, the  $\zeta$ -potentials of both cationic AuNPs did not show drastic changes, which is expected because DOPC and DOPC/DOPE are zwitterionic

(Figure 4e-h). However, the  $\zeta$ -potentials decreased and switched from positive to negative after interacting with 9:1 DOPC/DOPS or 9:1 DOPC/DOPG, providing compelling evidence for the binding of anionic DOPS or DOPG onto initially cationic AuNPs.




**Figure 4.** Hydrodynamic diameters and  $\zeta$ -potential of MTAB- and PAH-AuNPs before (red) and after (blue) lipid pull-down experiments, for lipid vesicles of a/e) DOPC, b/f) 9:1 DOPC/DOPS, c/g) 9:1 DOPC/DOPG, d/h) 9:1 DOPC/DOPE. Bar heights represent mean values; error bars indicate the standard error for 10 runs of DLS analysis or  $\zeta$ -potential measurements for representative samples.

All the above data qualitatively supports the notion that cationic colloidal nanoparticles can acquire lipids from vesicles. To be more quantitative, lipid concentrations in the supernatants, after nanoparticle pull-down, were measured by LC-MS/MS. Figure S4 shows representative raw data, compared to controls, which underwent the same centrifugation steps as all other samples but contained no nanoparticles. Significant decreases in the amount of lipids in the supernatants were observed for both types of cationic AuNPs in all vesicle systems, indicating the acquisition of lipids from the vesicles by both AuNPs. In Figure 5a, both types of AuNPs bound more than 80% of DOPC under the described conditions, and the amount of DOPC pulled down by the nanoparticles did not differ ( $p > 0.05$ ), indicating a lack of preference of DOPC binding to PAH-

1  
2  
3 AuNPs or to MTAB-AuNPs. However, when presented with both DOPS and DOPC (Figure 6b),  
4 PAH-AuNPs bound more than 95% of both lipids whereas MTAB-AuNPs bound less than 60%  
5 of lipids, with a strong preference for anionic DOPS relative to zwitterionic DOPC. Similar, but  
6 not identical, results were obtained for 9:1 DOPC/DOPG anionic vesicles (Figure 6c): PAH-  
7 AuNPs bound more lipids than MTAB-AuNPs. For zwitterionic 9:1 DOPC/DOPE vesicles, the  
8 two types of nanoparticles pulled down 85-95% of both lipids. Table S2 lists the characteristics  
9 for each batch of vesicles and nanoparticles for each data set in Figure 5.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 While these data themselves to not provide direct binding affinities for lipid-nanoparticle  
23 interactions, in initial experiments (data not shown) we found that 3X lower vesicle concentrations  
24 than the ones described above led to complete lipid pulldown by PAH-AuNPs. Related  
25 experiments from our group suggest that cationic gold nanoparticles irreversibly adsorb to  
26 supported lipid bilayers with  $\sim 1 \times 10^{11}$  particles/cm<sup>2</sup>, albeit under different conditions and for  
27 DOPC with a different co-lipid.<sup>28</sup> Taken together, these data provide qualitative context for the  
28 relative strength of lipid-NP interactions. Another question that might arise is: do the lipids replace  
29 MTAB and PAH on the particle surface, or do they merely associate with the surface-bound  
30 ligands? In the absence of quantitative data in which free MTAB or PAH is measured in  
31 supernatants, we suggest that lipid replacement is unlikely due to the strong Au-S bonds and  
32 hydrophobic tail interactions in the case of MTAB, and the multivalent electrostatic points of  
33 contact in the case of PAH. The surface chemistry and DLS/zeta potential data, taken together,  
34 suggest that the assumption of lipid acquisition by nanoparticles with intact surface ligands is a  
35 reasonable one.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 5.**  $C_{\text{bound}}/C_{\text{total}}$  percentage, after pull-down separation of AuNP pellets, based on LC-MS/MS quantification. The lipids are a) DOPC, b) 9:1 DOPC/DOPS, c) 9:1 DOPC/DOPG, d) 9:1 DOPC/DOPE. Bar heights represent mean values; error bars correspond to one standard deviation for triplicate runs from the same batches of nanoparticle and lipid vesicle solutions. The nanoparticle batches were independently synthesized for a, b, c, d, as were the lipid vesicle solutions. Asterisks correspond to the following  $p$  values using ANOVA followed by post hoc multiple comparisons test: \*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .


Batch-to-batch variation in zeta potential and hydrodynamic size does occur for both nanoparticles and lipid vesicles (Table S2, Figure S5). An example of analogous results for Figure 5, but with an unusual batch of MTAB-AuNPs (+ 46 mV zeta potential compared to the usual +15 mV; Figure S6b) shows that while the absolute magnitude of lipid pull-down is altered (more positive zeta potential does lead to more lipid binding), the general trends of Figure 5 are robust, and more lipids are pulled down by PAH-AuNPs compared to MTAB-AuNP, while very little are pulled down by

1  
2  
3 the anionic citrate-capped nanoparticles. The natural assumption is that electrostatic interactions  
4 dominate relations between vesicles and nanoparticles.<sup>47</sup> This is perhaps obvious, but the chemical  
5 nature of MTAB and PAH are quite different. For example, the quaternary ammonium headgroup  
6 of MTAB is a poor hydrogen bond donor or acceptor compared to PAH, whereas the  
7 hydrophobicity of MTAB is higher than PAH due to its C16 chain, which one could have  
8 postulated would have resulted in favorable hydrophobic interactions with the hydrophobic tails  
9 of lipids.<sup>40</sup> Furthermore, MTAB is a classic example of a self-assembled thiol on a gold surface  
10 via Au-S bonds, and is expected to display a rather packed, uniform cationic surface to the solvent.  
11 PAH, on the other hand, is a polymer that is electrostatically associated with the nanoparticle core,  
12 and, according to NMR experiments of it bound to other nanoparticles, it has segments farther  
13 away from the surface and in highly mobile environments (loops and tails).<sup>57</sup> The mobility of  
14 polymer segments or ligands on nanoparticles may potentially affect how they interact with lipid  
15 vesicles.<sup>13, 57</sup> It also has been reported previously that polymers bearing primary amines exceed  
16 their quaternary ammonium counterparts in membrane binding and disruption.<sup>48</sup> In spite of the  
17 many contributors to the thermodynamics of lipid-nanoparticle interactions that make quantitative  
18 predictions difficult (charge density, water and ion local concentrations, hydrophobic and  
19 electrostatic interactions, hydrogen bonding), we conclude that the primary amine, “loopy” surface  
20 of PAH is more likely to pull lipids out from vesicles than the quaternary ammonium “uniform”  
21 surface of MTAB.<sup>49</sup>

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 A large amount of evidence shows that cationic nanoparticles have more adverse outcomes than  
50 their anionic counterpart at the cellular level.<sup>12,37,50</sup> The evidence we present, that lipids are  
51 quantitatively extracted from vesicles by cationic nanoparticles, may provide a mechanism at the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 cellular level: lipid extraction from membranes by nanoparticles would disrupt the cell membranes  
4 and induce membrane damage which can eventually lead to cell death.<sup>51,52</sup> While MTAB-AuNPs  
5 have shown an excellent ability to be taken up by cells, the toxicity of MTAB itself to biological  
6 systems has not been reported yet,<sup>53,54</sup> but PAH seems to be rather cytotoxic.<sup>47,55,56</sup>  
7  
8  
9  
10  
11  
12  
13  
14

15 *Effects of purification method of AuNPs and other ratios of AuNPs:lipid vesicles.* The purification  
16 method of the nanomaterials used in this study above was twice-centrifugation. This rigorous  
17 purification scheme was chosen because it was found that an extra round of centrifugation can  
18 further reduce the amount of unbound PAH polymer in the nanoparticle solution by an order of  
19 magnitude, which eliminates most of the free PAH, resulting in a relatively clean system.<sup>56</sup>  
20 However, we noticed that PAH-AuNPs are less stable than MTAB-AuNPs, and they eventually  
21 aggregated in buffer after ~2 days. As a 1× centrifugation of PAH-AuNPs leads to more stable  
22 colloidal suspensions (but also leaves measurable quantities of free PAH in the supernatant), we  
23 also quantified the lipids pulled down by both MTAB- and PAH-AuNPs purified with 1×  
24 centrifugation. In these experiments, 500  $\mu$ L 4.8 nM AuNPs were added, respectively, in 500  $\mu$ L  
25 2, 20, or 200  $\mu$ g mL<sup>-1</sup> (at number ratio of 150:1, 15:1, 1.5:1) of two vesicles system (9:1  
26 DOPC/DOPS, 9:1 DOPC/DOPG), and underwent the same process of pull-down experiment as  
27 above described.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43



1  
2  
3 **Figure 6.**  $C_{\text{bound}}/C_{\text{total}}$  percentage, after pull-down separation of AuNP pellets, based on LC-  
4 MS/MS quantification, for 9:1 DOPC/DOPS (a-c) and 9:1 DOPC/DOPG (d-f), for 4.8 nM MTAB-  
5 and PAH- AuNPs interacting with a/d) 2  $\mu\text{g mL}^{-1}$ , b/e) 20  $\mu\text{g mL}^{-1}$ , c/f) 200  $\mu\text{g mL}^{-1}$  lipid vesicles,  
6 compared to controls. Bar heights represent mean values; error bars correspond to one standard  
7 deviation,  $n = 3$ , for three batches of nanoparticles and one batch of lipid vesicles. Asterisks  
8 correspond to the following  $p$  values using ANOVA followed by post hoc multiple comparisons  
9 test: \*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 With a competitor in the supernatant for lipids – free PAH – the comparison between MTAB-  
23 AuNPs and PAH-AuNPs is tilted far in apparent favor of MTAB, meaning PAH-AuNPs acquired  
24 much less lipids. The likely reason for the significant change in lipid association with the PAH-  
25 AuNPs is that free PAH (7.53  $\text{mg L}^{-1}$  per  $\text{mg L}^{-1}$  in supernatants of 1x centrifuged AuNPs, instead  
26 of 0.49  $\text{mg L}^{-1}$  in supernatants of 2x centrifuges AuNPs)<sup>56</sup> sequesters lipids and competes with  
27 PAH bound to nanoparticles. In this circumstance, lipids appear to prefer free PAH compared to  
28 nanoparticle-bound PAH. Details of the conformation of free PAH and bound PAH are doubtless  
29 involved in this discrimination, as well as considerations of possible differences in the relative  
30 binding energies of lipid/free PAH compared to lipid/bound PAH;<sup>57,58</sup> we note that previous NMR  
31 experiments of 4 nm PAH-AuNPs suggested that the PAH polymer is “loosened” upon lipid  
32 vesicle interaction.<sup>28</sup> The other interesting point about the data in Figure 6 is that even though  
33 lipid concentrations are increasing 100×,  $C_{\text{bound}}/C_{\text{total}}$  is only modestly affected, meaning  
34 absolutely more lipids are bound and are likely forming multilayers on cationic NP surfaces,  
35 similar to what we have observed before for both PAH and hydrophobic particle surfaces.<sup>18</sup>  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## CONCLUSION

In summary, we developed a centrifugation-based pull-down assay in which one anionic AuNP and two cationic AuNPs were incubated with four lipid vesicles systems. Collective data demonstrate both qualitatively and quantitatively that phospholipids in vesicles are extracted and bound to cationic AuNPs, indicating a lipid corona formation on both types of cationic AuNPs. Little lipid corona was formed on Citrate-AuNPs, supporting the electrostatic nature of the interactions. Different degrees of binding to both cationic AuNPs were observed in the binary vesicles systems, and different compositions of lipids may lead to different lipid coronas, independent of abundance of lipids. In the binary vesicle systems, the quantitative data show that PAH-AuNPs has higher tendency to extract lipids from the vesicles. We also note that insufficient purification of nanoparticle solutions can lead to free ligand, which competes for lipid binding and can give erroneous conclusions about NP-lipid affinities.

With the promising, though challenging, development of lipidomics by LC-MS/MS, we envision the work presented herein setting the stage for generation of a “lipid corona fingerprinting” database by quantitatively correlating lipid corona information to cellular uptake, membrane disruption, trafficking and cytotoxicity, to improve quantitative predictions of nano-bio interactions.<sup>32,59</sup>

## ACKNOWLEDGEMENTS

We thank the NSF Center for Sustainable Nanotechnology (Grant CHE-1503408) and its members for support, especially Professors Joel Pedersen and Christy Haynes. We thank Dr. Lucas Li,

1  
2  
3 Metabolomics Laboratory of the Roy J. Carver Biotechnology Center at UIUC, for the raw data of  
4  
5 lipid quantification.  
6  
7  
8  
9  
10

11 Supporting Information Available: Representative extinction spectra, TEM images and diameter  
12 histograms,  $\lambda_{max}$ ,  $d_h$ , and  $\zeta$ -potentials of citrate-AuNPs, MTAB-AuNPs and PAH-AuNPs; Raw  
13 quantification of lipids in the supernatants by LC-MS/MS;  $d_h$  and  $\zeta$ -potentials of two batches of  
14 lipid vesicles, MTAB-AuNPs and PAH-AuNPs used in different systems; batch-to-batch  
15 reproducibility data; LC-MS/MS method; Calculation of the number ratio of AuNPs:lipid vesicles;  
16  $\zeta$ -potentials of 16 batches of MTAB-AuNPs; MTAB synthesis and characterization.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

## REFERENCES

32  
33  
34  
35 (1) Murphy, C. J.; Sau, T. K.; Gole, A. M.; Orendorff, C. J.; Gao, J.; Gou, L.; Hunyadi, S. E.;  
36 Li, T. Anisotropic Metal Nanoparticles: Synthesis, Assembly, and Optical Applications. *J.  
37 Phys. Chem. B* **2005**, *109*, 13857–13870.  
38  
39  
40 (2) Saha, K.; Agasti, S. S.; Kim, C.; Li, X.; Rotello, V. M. Gold Nanoparticles in Chemical and  
41 Biological Sensing. *Chem. Rev.* **2012**, *112*, 2739–2779.  
42  
43  
44 (3) Murphy, C. J.; Gole, A. M.; Stone, J. W.; Sisco, P. N.; Alkilany, A. M.; Goldsmith, E. C.;  
45 Baxter, S. C. Gold Nanoparticles in Biology: Beyond Toxicity to Cellular Imaging. *Acc.  
46 Chem. Res.* **2008**, *41*, 1721–1730.  
47  
48  
49 (4) Ghosh, P.; Han, G.; De, M.; Kim, C. K.; Rotello, V. M. Gold Nanoparticles in Delivery  
50 Applications. *Adv. Drug Deliv. Rev.* **2008**, *60*, 1307–1315.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (5) Jain, S.; Hirst, D. G.; O'Sullivan, J. M. Gold Nanoparticles as Novel Agents for Cancer  
4 Therapy. *Br. J. Radiol.* **2012**, *85*, 101–113.

5  
6 (6) Dreaden, E. C.; Alkilany, A. M.; Huang, X.; Murphy, C. J.; El-Sayed, M. A. The Golden  
7 Age: Gold Nanoparticles for Biomedicine. *Chem. Soc. Rev.* **2012**, *41*, 2740–2779.

8  
9 (7) Abadeer, N. S.; Murphy, C. J. Recent Progress in Cancer Thermal Therapy Using Gold  
10 Nanoparticles. *J. Phys. Chem. C* **2016**, *120*, 4691–4716.

11  
12 (8) Verma, A.; Stellacci, F. Effect of Surface Properties on Nanoparticle-Cell Interactions.  
13  
14 *Small* **2010**, *6*, 12–21.

15  
16 (9) Albanese, A.; Tang, P. S.; Chan, W. C. W. The Effect of Nanoparticle Size, Shape, and  
17 Surface Chemistry on Biological Systems. *Annu. Rev. Biomed. Eng.* **2012**, *14*, 1–16.

18  
19 (10) Fadeel, B.; Garcia-Bennett, A. E. Better Safe than Sorry: Understanding the Toxicological  
20 Properties of Inorganic Nanoparticles Manufactured for Biomedical Applications. *Adv.*  
21  
22 *Drug Deliv. Rev.* **2010**, *62*, 362–374.

23  
24 (11) Guzmán, K. A. D.; Taylor, M. R.; Banfield, J. F. Environmental Risks of Nanotechnology:  
25 National Nanotechnology Initiative Funding, 2000-2004. *Environ. Sci. Technol.* **2006**, *40*,  
26 1401–1407.

27  
28 (12) Murphy, C. J.; Vartanian, A. M.; Geiger, F. M.; Hamers, R. J.; Pedersen, J.; Cui, Q.; Haynes,  
29 C. L.; Carlson, E. E.; Hernandez, R.; Klaper, R. D.; Orr, G.; Rosenzweig, Z. Biological  
30 Responses to Engineered Nanomaterials: Needs for the next Decade. *ACS Cent. Sci.* **2015**,  
31 *1*, 117–123.

32  
33 (13) Nel, A. E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig,  
34 F.; Castranova, V.; Thompson, M. Understanding Biophysicochemical Interactions at the  
35 Nano-Bio Interface. *Nat. Mater.* **2009**, *8*, 543–557.

36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (14) Gagner, J. E.; Shrivastava, S.; Qian, X.; Dordick, J. S.; Siegel, R. W. Engineering  
4 Nanomaterials for Biomedical Applications Requires Understanding the Nano-Bio  
5 Interface: A Perspective. *J. Phys. Chem. Lett.* **2012**, *3*, 3149–3158.  
6  
7 (15) Docter, D.; Westmeier, D.; Markiewicz, M.; Stolte, S.; Knauer, S. K.; Stauber, R. H. The  
8 Nanoparticle Biomolecule Corona: Lessons Learned - Challenge Accepted? *Chem. Soc. Rev.*  
9 **2015**, *44*, 6094–6121.  
10  
11 (16) Calzolai, L.; Franchini, F.; Gilliland, D.; Rossi, F. Protein-Nanoparticle Interaction:  
12 Identification of the Ubiquitin-Gold Nanoparticle Interaction Site. *Nano Lett.* **2010**, *10*,  
13 3101–3105.  
14  
15 (17) Melby, E. S.; Lohse, S. E.; Park, J. E.; Vartanian, A. M.; Putans, R. A.; Abbott, H. B.;  
16 Hamers, R. J.; Murphy, C. J.; Pedersen, J. A. Cascading Effects of Nanoparticle Coatings:  
17 Surface Functionalization Dictates the Assemblage of Complexed Proteins and Subsequent  
18 Interaction with Model Cell Membranes. *ACS Nano* **2017**, *11*, 5489–5499.  
19  
20 (18) Yang, J. A.; Murphy, C. J. Evidence for Patchy Lipid Layers on Gold Nanoparticle Surfaces.  
21 *Langmuir* **2012**, *28*, 5404–5416.  
22  
23 (19) Raesch, S. S.; Tenzer, S.; Storck, W.; Rurainski, A.; Selzer, D.; Ruge, C. A.; Perez-Gil, J.;  
24 Schaefer, U. F.; Lehr, C. M. Proteomic and Lipidomic Analysis of Nanoparticle Corona  
25 upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid  
26 Composition. *ACS Nano* **2015**, *9*, 11872–11885.  
27  
28 (20) Hu, M.; Stanzione, F.; Sum, A. K.; Faller, R.; Deserno, M. Design Principles for  
29 Nanoparticles Enveloped by a Polymer-Tethered Lipid Membrane. *ACS Nano* **2015**, *9*,  
30 9942–9954.  
31  
32 (21) Van Lehn, R. C.; Alexander-Katz, A. Fusion of Ligand-Coated Nanoparticles with Lipid  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Bilayers: Effect of Ligand Flexibility. *J. Phys. Chem. A* **2014**, *118*, 5848–5856.  
4  
5 (22) Van Lehn, R. C.; Alexander-Katz, A. Structure of Mixed-Monolayer-Protected  
6 Nanoparticles in Aqueous Salt Solution from Atomistic Molecular Dynamics Simulations.  
7  
8 *J. Phys. Chem. C* **2013**, *117*, 20104–20115.  
9  
10  
11 (23) Edidin, M. Lipids on the Frontier: A Century of Cell-Membrane Bilayers. *Nat. Rev. Mol.*  
12  
13 *Cell Biol.* **2003**, *4*, 414–418.  
14  
15  
16 (24) Hou, W.-C.; Moghadam, B. Y.; Corredor, C.; Westerhoff, P.; Posner, J. D. Distribution of  
17 Functionalized Gold Nanoparticles between Water and Lipid Bilayers as Model Cell  
18 Membranes. *Environ. Sci. Technol.* **2012**, *46*, 1869–1876.  
19  
20  
21  
22 (25) Roiter, Y.; Ornatska, M.; Rammohan, A. R.; Balakrishnan, J.; Heine, D. R.; Minko, S.  
23 Interaction of Nanoparticles with Lipid Membrane. *Nano Lett.* **2008**, *8*, 941–944.  
24  
25  
26 (26) Van Lehn, R. C.; Atukorale, P. U.; Carney, R. P.; Yang, Y. S.; Stellacci, F.; Irvine, D. J.;  
27 Alexander-Katz, A. Effect of Particle Diameter and Surface Composition on the  
28 Spontaneous Fusion of Monolayer-Protected Gold Nanoparticles with Lipid Bilayers. *Nano*  
29  
30 *Lett.* **2013**, *13*, 4060–4067.  
31  
32  
33  
34 (27) Chen, K. L.; Bothun, G. D. Nanoparticles Meet Cell Membranes: Probing Nonspecific  
35 Interactions Using Model Membranes. *Environ. Sci. Technol.* **2014**, *48*, 873–880.  
36  
37  
38 (28) Troiano, J. M.; Olenick, L. L.; Kuech, T. R.; Melby, E. S.; Hu, D.; Lohse, S. E.; Mensch,  
39 A. C.; Dogangun, M.; Vartanian, A. M.; Torelli, M. D.; Ehimiaghe, E.; Walter, S. R.; Fu,  
40 L.; Anderton, C. R.; Zhu, Z.; Wang, H.; Orr, G.; Murphy, C. J.; Hamers, R. J.; Pedersen, J.  
41 A.; Geiger, F. M. Direct Probes of 4 nm Diameter Gold Nanoparticles Interacting with  
42 Supported Lipid Bilayers. *J. Phys. Chem. C* **2015**, *119*, 534–546.  
43  
44  
45 (29) Olenick, L. L.; Troiano, J. M.; Vartanian, A.; Melby, E. S.; Mensch, A. C.; Zhang, L.; Hong,  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 J.; Qiu, T.; Bozich, J.; Lohse, S.; Zhang, X.; Kuech, T. R.; Millevolte, A.; Gunsolus, I.;  
4  
5 McGeachy, A. C.; Dogangun, M.; Li, T.; Hu, D.; Walter, S. R.; Mohaimani, A.; Schmoldt,  
6  
7 A.; Torelli, M. D.; Hurley, K. R.; Dalluge, J.; Chong, G.; Feng, Z. V.; Haynes, C. L.; Hamers,  
8  
9 R. J.; Pedersen, J. A.; Cui, Q.; Hernandez, R.; Klaper, R.; Orr, G.; Murphy, C. J.; Geiger, F.  
10  
11 Lipid Corona Formation from Nanoparticle Interactions with Bilayers and Membrane-  
12  
13 Specific Biological Outcomes. **2017**, <https://doi.org/10.26434/chemrxiv.5512996.v1>.  
14  
15

16 (30) Bekdemir, A.; Stellacci, F. A Centrifugation-Based Physicochemical Characterization  
17 Method for the Interaction between Proteins and Nanoparticles. *Nat. Commun.* **2016**, *7*,  
18 13121.  
19  
20 (31) Xi, A.; Bothun, G. D. Centrifugation-Based Assay for Examining Nanoparticle-Lipid  
21 Membrane Binding and Disruption. *Analyst* **2014**, *139*, 973–981.  
22  
23 (32) Walkey, C. D.; Olsen, J. B.; Song, F.; Liu, R.; Guo, H.; Olsen, D. W. H.; Cohen, Y.; Emili,  
24 A.; Chan, W. C. W. Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold  
25 and Silver Nanoparticles. *ACS Nano* **2014**, *8*, 2439–2455.  
26  
27 (33) Vigderman, L.; Manna, P.; Zubarev, E. R. Quantitative Replacement of Cetyl  
28 Trimethylammonium Bromide by Cationic Thiol Ligands on the Surface of Gold Nanorods  
29 and Their Extremely Large Uptake by Cancer Cells. *Angew. Chemie - Int. Ed.* **2012**, *51*,  
30 636–641.  
31  
32 (34) Turkevich, J.; Stevenson, P. C.; Hillier, J. A Study of the Nucleation and Growth Processes  
33 in the Synthesis of Colloidal Gold. *Discuss. Faraday Soc.* **1951**, *11*, 55–75.  
34  
35 (35) Haiss, W.; Thanh, N. T. K.; Aveyard, J.; Fernig, D. G. Determination of Size and  
36 Concentration of Gold Nanoparticles from UV-Vis Spectra. *Anal. Chem.* **2007**, *79*, 4215–  
37 4221.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3 (36) Buchman, J. T.; Rahnamoun, A.; Landy, K. M.; Zhang, X.; Vartanian, A. M.; Jacob, L. M.;  
4 Murphy, C. J.; Hernandez, R.; Haynes, C. L. Using an Environmentally-Relevant Panel of  
5 Gram-Negative Bacteria to Assess the Toxicity of Polyallylamine Hydrochloride-Wrapped  
6 Gold Nanoparticles. *Environ. Sci. Nano* **2018**, *5*, 279–288.  
7  
8 (37) Bozich, J. S.; Lohse, S. E.; Torelli, M. D.; Murphy, C. J.; Hamers, R. J.; Klaper, R. D.  
9 Surface Chemistry, Charge and Ligand Type Impact the Toxicity of Gold Nanoparticles to  
10 Daphnia Magna. *Environ. Sci. Nano* **2014**, *1*, 260–270.  
11  
12 (38) Troiano, J. M.; McGeachy, A. C.; Olenick, L. L.; Fang, D.; Liang, D.; Hong, J.; Kuech, T.  
13 R.; Caudill, E. R.; Pedersen, J. A.; Cui, Q.; Geiger, F. M. Quantifying the Electrostatics of  
14 Polycation–Lipid Bilayer Interactions. *J. Am. Chem. Soc.* **2017**, *139*, 5808–5816.  
15  
16 (39) Yang, J. A.; Lin, W.; Woods, W. S.; George, J. M.; Murphy, C. J.  $\alpha$ -Synuclein’s Adsorption,  
17 Conformation, and Orientation on Cationic Gold Nanoparticle Surfaces Seeds Global  
18 Conformation Change. *J. Phys. Chem. B* **2014**, *118*, 3559–3571.  
19  
20 (40) Lin, W.; Insley, T.; Tuttle, M. D.; Zhu, L.; Berthold, D. A.; Král, P.; Rienstra, C. M.;  
21 Murphy, C. J. Control of Protein Orientation on Gold Nanoparticles. *J. Phys. Chem. C* **2015**,  
22 *119*, 21035–21043.  
23  
24 (41) Geiger, O.; López-Lara, I. M.; Sohlenkamp, C. Phosphatidylcholine Biosynthesis and  
25 Function in Bacteria. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* **2013**, *1831*, 503–513.  
26  
27 (42) Martínez-Morales, F.; Schobert, M.; López-Lara, I. M.; Geiger, O. Pathways for  
28 Phosphatidylcholine Biosynthesis in Bacteria. *Microbiology* **2003**, *149*, 3461–3471.  
29  
30 (43) Ghosh, S. K.; Pal, T. Interparticle Coupling Effect on the Surface Plasmon Resonance of  
31 Gold Nanoparticles: From Theory to Applications. *Chem. Rev.* **2007**, *107*, 4797–4862.  
32  
33 (44) Wang, B.; Zhang, L.; Bae, S. C.; Granick, S. Nanoparticle-Induced Surface Reconstruction  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of Phospholipid Membranes. *Proc. Natl. Acad. Sci.* **2008**, *105*, 18171–18175.  
4  
5 (45) Van Lehn, R. C.; Ricci, M.; Silva, P. H. J.; Andreozzi, P.; Reguera, J.; Voïtchovsky, K.;  
6 Stellacci, F.; Alexander-Katz, A. Lipid Tail Protrusions Mediate the Insertion of  
7 Nanoparticles into Model Cell Membranes. *Nat. Commun.* **2014**, *5*, 4482.  
8  
9 (46) Su, K. H.; Wei, Q. H.; Zhang, X.; Mock, J. J.; Smith, D. R.; Schultz, S. Interparticle  
10 Coupling Effects on Plasmon Resonances of Nanogold Particles. *Nano Lett.* **2003**, *3*, 1087–  
11 1090.  
12  
13 (47) Torrano, A. A.; Pereira, Â. S.; Oliveira, O. N.; Barros-Timmons, A. Probing the Interaction  
14 of Oppositely Charged Gold Nanoparticles with DPPG and DPPC Langmuir Monolayers  
15 as Cell Membrane Models. *Colloids Surfaces B Biointerfaces* **2013**, *108*, 120–126.  
16  
17 (48) Palermo, E. F.; Lee, D. K.; Ramamoorthy, A.; Kuroda, K. Role of Cationic Group Structure  
18 in Membrane Binding and Disruption by Amphiphilic Copolymers. *J. Phys. Chem. B* **2011**,  
19 *115*, 366–375.  
20  
21 (49) De, M.; You, C. C.; Srivastava, S.; Rotello, V. M. Biomimetic Interactions of Proteins with  
22 Functionalized Nanoparticles: A Thermodynamic Study. *J. Am. Chem. Soc.* **2007**, *129*,  
23 10747–10753.  
24  
25 (50) Fröhlich, E. The Role of Surface Charge in Cellular Uptake and Cytotoxicity of Medical  
26 Nanoparticles. *Int. J. Nanomedicine* **2012**, *7*, 5577–5591.  
27  
28 (51) Van Lehn, R. C.; Alexander-Katz, A. Penetration of Lipid Bilayers by Nanoparticles with  
29 Environmentally-Responsive Surfaces: Simulations and Theory. *Soft Matter* **2011**, *7*, 11392.  
30  
31 (52) Cheng, X.; Zhang, W.; Ji, Y.; Meng, J.; Guo, H.; Liu, J.; Wu, X.; Xu, H. Revealing Silver  
32 Cytotoxicity Using Au Nanorods/Ag Shell Nanostructures: Disrupting Cell Membrane and  
33 Causing Apoptosis through Oxidative Damage. *RSC Adv.* **2013**, *3*, 2296–2305.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (53) Wang, C.; Sun, A.; Qiao, Y.; Zhang, P.; Ma, L.; Su, M. Cationic Surface Modification of  
4 Gold Nanoparticles for Enhanced Cellular Uptake and X-Ray Radiation Therapy. *J. Mater.*  
5 *Chem. B* **2015**, *3*, 7372–7376.  
6  
7 (54) Zarska, M.; Novotny, F.; Havel, F.; Sramek, M.; Babelova, A.; Benada, O.; Novotny, M.;  
8 Saran, H.; Kuca, K.; Musilek, K.; Hvezdova, Z.; Dzijak, R.; Vancurova, M.; Krejcikova,  
9 K.; Gabajova, B.; Hanzlikova, H.; Kyjacova, L.; Bartek, J.; Proska, J.; Hodny, Z. Two-Step  
10 Mechanism of Cellular Uptake of Cationic Gold Nanoparticles Modified by (16-  
11 Mercaptohexadecyl)Trimethylammonium Bromide. *Bioconjug. Chem.* **2016**, *27*, 2558–  
12 2574.  
13  
14 (55) Feng, Z. V.; Gunsolus, I. L.; Qiu, T. A.; Hurley, K. R.; Nyberg, L. H.; Frew, H.; Johnson,  
15 K. P.; Vartanian, A. M.; Jacob, L. M.; Lohse, S. E.; Torelli, M. D.; Hamers, R. J.; Murphy,  
16 C. J.; Haynes, C. L. Impacts of Gold Nanoparticle Charge and Ligand Type on Surface  
17 Binding and Toxicity to Gram-Negative and Gram-Positive Bacteria. *Chem. Sci.* **2015**, *6*,  
18 5186–5196.  
19  
20 (56) Qiu, T. A.; Torelli, M. D.; Vartanian, A. M.; Rackstraw, N. B.; Buchman, J. T.; Jacob, L.  
21 M.; Murphy, C. J.; Hamers, R. J.; Haynes, C. L. Quantification of Free Polyelectrolytes  
22 Present in Colloidal Suspension, Revealing a Source of Toxic Responses for  
23 Polyelectrolyte-Wrapped Gold Nanoparticles. *Anal. Chem.* **2017**, *89*, 1823–1830.  
24  
25 (57) Zhang, Y.; Fry, C. G.; Pedersen, J. A.; Hamers, R. J. Dynamics and Morphology of  
26 Nanoparticle-Linked Polymers Elucidated by Nuclear Magnetic Resonance. *Anal. Chem.*  
27 **2017**, *89*, 12399–12407.  
28  
29 (58) Chong, G.; Hernandez, R. Adsorption Dynamics and Structure of Polycations on Citrate-  
30 Coated Gold Nanoparticles. *J. Phys. Chem. C* **2018**, *122*, 19962–19969.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (59) Köfeler, H. C.; Fauland, A.; Rechberger, G. N.; Trötzmüller, M. Mass Spectrometry Based  
4  
5 Lipidomics: An Overview of Technological Platforms. *Metabolites* **2012**, *2*, 19–38.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 For TOC only  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60